Table 1.
Baseline patient characteristics in relation to unplanned hospitalization during chemotherapy.
| Unplanned hospitalization during chemotherapy | ||||
|---|---|---|---|---|
| No | Yes | Total | P-value | |
| Number of patients | 134 | 65 | 199 | |
| Age (years) | .19 | |||
| Mean (SD) | 73.3 (6.43) | 74.7 (6.96) | 73.7 (6.63) | |
| Median (range) | 72 (65-94) | 75 (65-89) | 73 (65-94) | |
| Sex, n (column%) | .02 | |||
| Female | 67 (50.0%) | 44 (67.7%) | 111 (55.8%) | |
| Male | 67 (50.0%) | 21 (32.3%) | 88 (44.2%) | |
| Race/ethnicity, n (column%) | .17 | |||
| White | 104 (77.6%) | 56 (86.2%) | 160 (80.4%) | |
| Black | 13 (9.7%) | 4 (6.2%) | 17 (8.5%) | |
| Asian | 9 (6.7%) | 5 (7.7%) | 14 (7.0%) | |
| Other | 8 (6.0%) | 0 (0.0%) | 8 (4.0%) | |
| Education, n (column%) | .59 | |||
| High school or less | 52 (38.8%) | 30 (46.2%) | 82 (41.2%) | |
| College graduate | 54 (40.3%) | 24 (36.9%) | 78 (39.2%) | |
| Advanced degree | 28 (20.9%) | 11 (16.9%) | 39 (19.6%) | |
| Marital status, n (column%) | .08 | |||
| Married | 81 (60.4%) | 48 (73.8%) | 129 (64.8%) | |
| Widowed | 24 (17.9%) | 11 (16.9%) | 35 (17.6%) | |
| Single/separated/divorced | 29 (21.6%) | 6 (9.2%) | 35 (17.6%) | |
| Household composition, n (column%) | .66 | |||
| Alone | 24 (18.2%) | 10 (15.6%) | 34 (17.1%) | |
| With someone | 108 (81.8%) | 54 (84.4%) | 162 (81.4%) | |
| Missing | 2 | 1 | 3 | |
| Employment, n (column%) | .47 | |||
| Employed | 25 (18.7%) | 12 (18.8%) | 37 (18.6%) | |
| Retired, homemaker, unemployed | 102 (76.1%) | 51 (79.7%) | 153 (76.9%) | |
| Disabled/medical leave | 7 (5.2%) | 1 (1.6%) | 8 (4.0%) | |
| Missing | 0 | 1 | 1 | |
| Body mass index (kg/m2) | .81 | |||
| Median (range) | 25.2 (15.2-44.0) | 24.8 (19.9-36.9) | 25.0 (15.2-44.0) | |
| Missing | 0 | 1 | 1 | |
| Cancer type, n (column%) | .08 | |||
| Colorectal | 64 (47.8%) | 21 (32.3%) | 85 (42.7%) | |
| Gastric/esophageal | 29 (21.6%) | 22 (33.8%) | 51 (25.6%) | |
| Pancreatic/hepatobiliary | 41 (30.6%) | 22 (33.8%) | 63 (31.7%) | |
| Cancer stage, n (column%) | .08 | |||
| I/II | 21 (15.7%) | 5 (7.7%) | 26 (13.1%) | |
| III | 42 (31.3%) | 15 (23.1%) | 57 (28.6%) | |
| IV | 71 (53.0%) | 45 (69.2%) | 116 (58.3%) | |
| Line of chemotherapy, n (column%) | .73 | |||
| First line | 102 (76.1%) | 48 (73.8%) | 150 (75.4%) | |
| >First line | 32 (23.9%) | 17 (26.2%) | 49 (24.6%) | |
| Number of chemotherapy agents, n (column%) | .62 | |||
| Single | 46 (34.3%) | 20 (30.8%) | 66 (33.2%) | |
| Poly | 88 (65.7%) | 45 (69.2%) | 133 (66.8%) | |
| Standard dose, n (column%) | .86 | |||
| No | 56 (41.8%) | 28 (43.1%) | 84 (42.2%) | |
| Yes | 78 (58.2%) | 37 (56.9%) | 115 (57.8%) | |
| Use of granulocyte colony-stimulating factor, n (column%) | ||||
| No | 107 (79.9%) | 48 (73.8%) | 155 (77.9%) | .34 |
| Yes | 27 (20.1%) | 17 (26.2%) | 44 (22.1%) | |
SD is a standard abbreviation. P-values were obtained from t-test for continuous variables and chi-square test for categorical variables.